Evidence map›Paper›PMID 41170377›Full record

SynthesisFrontiers in pharmacology2025

Reported associations between kratom and seizures: a systematic review.

Toby Turla, Grayson Abele, My Hua, Dennis Paustenbach

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Toby TurlaPaustenbach and Associates, Denver, CO, United States.
Grayson AbelePaustenbach and Associates, Denver, CO, United States.
My HuaPaustenbach and Associates, Glendale, CA, United States.
Dennis PaustenbachPaustenbach and Associates, Jackson, WY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statement of purpose innovation or hypothesis: Kratom, derived from the leaves of the plant Description of methods and materials: A systematic literature search was conducted to identify reviewed articles that contained information or data on kratom users experiencing seizures. Additionally, we mined adverse event data submitted to the Centers for Food Safety and Applied Nutrition's Adverse Event Reporting System (CAERS) database and the US FDA Adverse Event Reporting System (FAERS). These databases were selected to examine consumer-reported and healthcare-reported adverse event, providing a comprehensive list of seizure-related incidents potentially associated with kratom use. Data and results: Our search yielded a total of 42 articles, but only 11 met the selection criteria for inclusion. The 11 peer-reviewed articles included for analysis consisted of case reports (n = 6), case series (n = 2), retrospective observational (n = 2), and a paper discussing a summary of adverse events reported to the FAERS database. Across the 11 publications used in our analysis, we noted a total of 20 patients who reportedly experienced seizures after using kratom. However, only one patient was quantitatively positive for Mitragynine in their urine sample, so there was minimal proof of kratom use. There was no indication that the other 19 patients had their urine subjected to mitragynine screening which would have confirmed their use of kratom and internal metabolism after intake. Furthermore, the FAERS dashboard, only 22 of 481 kratom-related reports involved seizure (4.5%); the CAERS database had 18 reported seizures amongst 221,178 kratom-related incidents. Information regarding the quantity of kratom consumption or confirmed use of kratom was not available in any of the datasets reviewed. Interpretation conclusion or significance: Currently, the available literature primarily consists of a limited number of studies, including case reports and case series, which document self-reported kratom use and provide minimal quantitative toxicological data on mitragynine. Based on our narrative review, we conclude that there is insufficient evidence to suggest that kratom causes seizures, primarily due to the absence of a quantitative dose-response in toxicology reports, a incomplete medical records and because seizures occur relatively frequently in the general population.

Indexed as

7-hydroxymitragynineherbal supplementskratommitragyninepolysubstance-useseizures

Identifiers

PMID41170377
PMCPMC12568553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.